GW Pharmaceuticals (GWPH) announced its Q3 2019 earnings recently. Its earnings beat analysts' expectations, but the stock still closed down by 17% based on this news. I believe that there is a good buying opportunity after this drop. For starters, the earnings were good as both EPS and revenue beat expectations. Secondly, there is a catalyst coming up in December that could quickly turn things around. Lastly, the pipeline is extensive and I think it is poor to base the company's value only on Epidiolex with the currently approved indications. I think that